Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 proof-of-concept trial evaluating the efficacy of XEN901 as a treatment for adult focal seizures or for rare, pediatric forms of epilepsy

Trial Profile

A Phase 2 proof-of-concept trial evaluating the efficacy of XEN901 as a treatment for adult focal seizures or for rare, pediatric forms of epilepsy

Planning
Phase of Trial: Phase II

Latest Information Update: 29 Aug 2018

At a glance

  • Drugs XEN 901 (Primary)
  • Indications Epilepsy; Seizures
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Xenon Pharmaceuticals
  • Most Recent Events

    • 29 Aug 2018 According to a Xenon Pharmaceuticals media release, upon completion of a phase 1 trial of XEN901 and read-out of its final results (CT profile 282613), the company expects to initiate this trial as soon as feasible thereafter depending on planned discussions with regulatory agencies in the near term.
    • 11 Jan 2018 New trial record
    • 08 Jan 2018 According to a Xenon Pharmaceuticals media release, this trial is expected to begin by year-end 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top